Initiatives to increase the prescribing of low cost generics :

Simple item page
dc.contributor.authorGodman, Brian
dc.contributor.authorBaker, Amanj
dc.contributor.authorLeporowski, Axel
dc.contributor.authorMorton, Alec
dc.contributor.authorBaumgärte, Christoph
dc.contributor.authorBochenek, Tomasz
dc.contributor.authorFadare, Joseph
dc.contributor.authorFinlayson, Alexander
dc.contributor.authorHussain, Shazhad
dc.contributor.authorKhan, Babar
dc.contributor.authorKalaba, Marija
dc.contributor.authorKibuule, Dan
dc.contributor.authorKwon, Hye-Young
dc.contributor.authorMelien, Oyvind
dc.contributor.authorNascimento, Renata CRM
dc.contributor.authorSalem, Ahmed
dc.contributor.authorSchiffers, Krijn
dc.contributor.authorTruter, Ilse
dc.contributor.authorVoncina, Luka
dc.contributor.authorHassali, Mohamed Azmi
dc.date.accessioned2023-08-25T10:10:06Z
dc.date.available2023-08-25T10:10:06Z
dc.date.issued2017
dc.descriptionJournal article
dc.description.abstractGetting the most out of the pharmaceutical budget is critical across all countries as the financial pressures on healthcare systems intensify. In this paper, we review global practice on encouraging the use of low costs generics versus branded pharmaceuticals, including patented products in the same class where care is not compromised, across countries to guide future practice. Our review ranges widely across European countries as well as other high income countries, including Abu Dhabi, Japan and the USA, and other low and middle income countries. There is a particular focus on Scotland, building on previous publications. We conclude based on multiple publications, including several case studies, that achieving efficiency in pharmaceutical spending is possible in virtually all environments, although there are examples of technologies where generic or therapeutic substitution should not be encouraged. However, there is no magic bullet to achieving full and appropriate use of generics. Countries have to be prepared to use a number of different education, economic, engineering and enforcement methods including prescribing restrictions to achieve success. Similarly, different approaches to achieve low prices for good quality generics given the considerable price differences that currently exist. The combination of low prices and increased use of generics will help achieve or attain universal healthcare, benefiting all key stakeholder groups. We conclude with a call for greater cross-country learning in pursuit of what should be a common goal for all health systems. Keywords: Co-payments, compulsory substitution, generics, prescribing restrictions, prices, reforms, Scotland
dc.description.sponsorshipStrathclyde University, Glasgow, University Hospital Huddinge, Busitema University
dc.identifier.citationGodman, B., Kurdi, A., Leporowski, A., Morton, A., Baumgärtel, C., Bochenek, T., ... & Hassali, A. (2017). Initiatives to increase the prescribing of low cost generics: the case of Scotland in the international context. Medical Research Archives, 5(3).
dc.identifier.urihttps://doi.org/10.60682/t1ye-hp24
dc.language.isoen
dc.publisherKEIJournals
dc.relation.ispartofseriesMedical Research Archives ; Volume 3, Issue 3
dc.subjectResearch Subject Categories::NATURAL SCIENCES::Biology::Cell and molecular biology::Genetics
dc.titleInitiatives to increase the prescribing of low cost generics :
dc.title.alternativethe case of Scotland in the international context
dc.typeArticle
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed to upon submission
Description:
Download
Collections
Department of Clinical Phamacology